According to the World Cancer Research Fund, prostate cancer is the most common type of cancer among men in the UK – in fact, in 2021, it made up for more than a quarter of all new cases in the country, signalling an alarming trend in the UK’s national health interests.
A massive part of mitigating the risks of elevating numbers of prostate cancer diagnoses in the UK is attempting to have more people tested and evaluated as early as possible. While this isn’t always the rule, the general concensus among health professionals is that the earlier the cancer is caught, the better the prognosis.
However, understanding this issue is one thing, but having a national health department like NHS respond to it is another. Previously, the NHS has been doing a lot of what it’s done as a result of advice provided by the National Institute of Health and Care Excellence (NICE). This advice asserted that prostate cancer testing ought to be available to men over the age of 50, however, this age threshold has been a topic of contention for quite some time.
An Increase in Cases of Prostate Cancer in Young Men?
Over the last few years, several celebrities in particular have spoken up about the apparent increase in the number of young men being diagnosed with prostate cancer, including the likes of Sir Chris Hoy, an award-winning cyclist who was only 47 when he received his diagnosis – three years under the NHS’s official age threshold.
Understandably, this has become a growing concern among health professionals and men in the UK more broadly, with the overwhelming sentiment seemingly becoming that this age threshold was no longer relevant to the UK’s reality.
However, while many have been actively campaigning to increase screening and testing among younger Set featured imagemen in the UK, there’s also been some resistance, with those in opposition asserting their doubt in the reliabilty in some of the testing methods commonly used. The idea was that the threshold for those eligible for screening ought to be lowered and more inclusive – not only lowering the age, but specifically allowing for those most at risk to receive screening. In the UK, that includes both men with family history of prostate cancer as well as black men who, statistically, are more vulnerable.
Prostate Cancer UK (PCUK) explained that the issue with so-called “unreliable screening and testing” was the lack of evidence-based guidance. The charity asserted that the best way to introduce targeted testing was to give more attention to active surveillance early on. Ultimately, the belief is that if we look out for prostate cancer more broadly and in younger patients, it’ll be easier to detect early signs and instances of prostate cancer.
Thus, there have been widespread calls for NICE to amend its advice to the NHS and include further evidence about the use of active surveillance in early prostate cancer detection.
More from Startups
- Top 5 Blockchain Startups in New Zealand 2025
- What To Do When Your Startup’s MVP Fails
- Want To Secure Startup Funding in India? Here’s How
- Data Analytics for Startups: Why It Matters More Than You Think
- How To Secure Startup Funding in South Africa
- Founding While Female: What Female Entrepreneurs Want the World to Hear on Women’s Equality Day 2025
- Founder of the Week: Alex Warner
- Startup of the Week: Healf
What Could This Mean for UK-Based MedTech Startups?
If the NHS does move to lower prostate cancer testing thresholds and target younger, previously excluded groups, it could open a new chapter for UK-based MedTech innovators. And that’s exciting, because it means a shift from reacting to demand to actually shaping it.
For starters, startups focused on diagnostics could find fresh opportunities. Smarter, more accessible PSA testing, quicker referrals, or tailored digital risk-assessment tools might suddenly become high-priority for GPs, clinics or even public health initiatives. And, if the NHS places a greater emphasis on active and targeted testing, that would signal a clear invitation to bring agile, patient-centred solutions direct to the frontline of healthcare.
But, it’s not just about opportunity. Bringing new testing approaches into the NHS system tends to be a marathon, not a sprint. It still means navigating regulatory hoops, demonstrating clear clinical value and cost-effectiveness and aligning with NHS pathways that can be slow to change. That’s where strategic collaboration becomes vital – forging partnerships with clinical trial networks, GP practices or national projects could accelerate acceptance and integration.
And, finally, early testing means screening younger men. That in turn raises expectations for ease-of-use, affordability and engagement -– areas where nimble UK startups often excel. So, if the NHS really does shift focus to more proactive, inclusive prostate cancer testing, it won’t just be a policy change. It could be a springboard for MedTech startups ready to deliver smarter, more human-centred diagnostics at scale.
